IL6 and encephalomyelitis: In vitro, both vitamers were shown to limit the production of interleukin-6 (IL-6) and other proinflammatory cytokines through the inhibtion of nuclear factor kappaB [12,13,14] whereas, in vivo, MK-4 limited inflammation in encephalomyelitis [15].